Must Read
Samsung announced it would increase spending on capital expenditures and R&D to $205B, a ~33% increase, over the next three years.
Though the South Korean conglomerate did not specify which business units will benefit from the new spending, it is looking to expand its logic-chip and memory-chip businesses and biopharmaceutical business arms.
Samsung also stated it is looking to make a major acquisition in artificial intelligence, 5G mobile networks, or automotive tech within the next three years.
In May, Samsung Biologics signed a deal with Moderna to provide fill-and-finish packaging for its COVID-19 vaccine.
Samsung Biologics plans to build two new plants in its hub in Incheon, bringing its plant count to six, as it hopes to expand its footprint in vaccine production.
During its Q2 earnings call last month, Samsung’s battery arm, Samsung SDI Co., announced it would enter the electric-vehicle battery market. The company is looking to build a new battery plant in Illinois.
Samsung also plans to enter the semiconductor manufacturing business, with a possible factory in the U.S.
The company is considering Arizona, New York, and Texas as possible locations for its $17B chip factory.
Samsung’s heir apparent, Lee Jae-Yong, was released from a Korean prison on parole on Aug. 13. He was found guilty of bribery and embezzlement in January.
The pandemic saw a major shortage in semiconductor chips which caused delays in several industries, particularly the automotive industry, with some plants temporarily shutting down.
Taiwan Semiconductor Manufacturing Co., the top chipmaker globally, is planning to invest ~$100B over the next three years to expand its chip manufacturing capacity.
Earlier this year, Intel Corp. announced plans to invest $20B in new semiconductor manufacturing factories.
Intel is also looking to buy GlobalFoundries Inc., a specialist chip production company, in a deal valued at ~$30B.